Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
Authors
Keywords
Overall Survival, Oxaliplatin, BRAF Mutation, Adjuvant FOLFOX, Pathologic Nodal Stage
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 24, Issue 5, Pages 1289-1294
Publisher
Springer Nature
Online
2016-11-17
DOI
10.1245/s10434-016-5682-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials
- (2017) D. J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) R. Labianca et al. ANNALS OF ONCOLOGY
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- Oncologic Outcomes after Adjuvant Chemotherapy Using FOLFOX in MSI-H Sporadic Stage III Colon Cancer
- (2013) Seung Yeop Oh et al. WORLD JOURNAL OF SURGERY
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
- (2012) P. G. Gavin et al. CLINICAL CANCER RESEARCH
- Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
- (2011) A. Zaanan et al. CLINICAL CANCER RESEARCH
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
- (2011) S. Ogino et al. CLINICAL CANCER RESEARCH
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
- (2011) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- (2011) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting
- (2009) Lucia I. H. Overbeek et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy
- (2009) Seung Tae Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
- (2009) Monica M. Bertagnolli et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group
- (2008) C. I. Müller et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started